Pragmatech funding supports commercial expansion of iAST®
Spanish HealthTech startup Pragmatech has raised €650,000 in fresh funding to accelerate the commercial rollout of its CE-marked AI antibiotic prescribing software, iAST®. The funding will support deployment across hospitals and healthcare providers, following regulatory approval earlier in 2025.
Based in Oviedo, Pragmatech focuses on applying artificial intelligence to pharmacology, microbiology, and infectious disease management. The company was founded in 2021 and operates on a B2B model, selling its software directly to healthcare organisations.
Funding round details and investors
The €650k funding round brings together venture capital, public financing, and the conversion of earlier investor commitments.
Key elements of the round include:
• First Drop leading the round with a €300,000 investment
• Urriellu Ventures contributing €175,000
• An ENISA loan worth €180,000
• Conversion of €162,500 in convertible notes from a previous round into equity
This mix of private and public funding provides Pragmatech with the financial runway needed to move from regulatory approval to scaled commercial adoption.
What is iAST® and why it matters
Pragmatech’s flagship product, iAST®, is positioned as the first CE-marked AI-powered software designed specifically to support clinical decision-making in antibiotic prescribing.
According to the company, iAST®:
• Analyses microbiological and pharmacological data to support treatment decisions
• Reduces antibiotic prescribing errors in clinical settings
• Recommends treatments with lower resistance potential
• Supports safer and more consistent prescribing practices
Antimicrobial resistance remains a major global healthcare challenge. Tools that help clinicians choose the most appropriate antibiotics are increasingly seen as critical for improving patient outcomes and preserving the effectiveness of existing drugs.
CE marking unlocks hospital deployment
Pragmatech’s iAST® software received CE marking in July 2025, a key regulatory milestone that enables commercial use across European healthcare systems.
CE marking confirms that the software meets EU requirements for safety, performance, and clinical benefit. For hospitals, this is often a prerequisite for procurement and integration into clinical workflows.
The new funding allows Pragmatech to move beyond pilots and validation projects into broader hospital adoption.
Leadership perspective on the funding
Javier Fernández, co-CEO of Pragmatech, said the funding strengthens the company’s ability to reach healthcare professionals who need decision-support tools in infectious disease management.
He noted that investor backing reflects growing confidence in the platform’s clinical impact and real-world value for hospitals.
Co-CEO and CTO Pablo Valledor highlighted the importance of continuing product development alongside commercial growth.
He said the investment will support further refinement of iAST® and ensure that artificial intelligence is applied in a safe and effective way within clinical decision-making processes.
Business model and long-term vision
Pragmatech operates a B2B model, targeting hospitals and healthcare providers rather than individual clinicians or patients.
The company’s broader goal is to support the digital transformation of infectious disease management by:
• Improving clinical decision-making quality
• Enhancing patient outcomes
• Supporting healthcare system sustainability
• Reducing the long-term impact of antimicrobial resistance
By combining AI with validated clinical workflows, Pragmatech aims to position itself as a long-term technology partner for healthcare institutions.
What comes next for Pragmatech
With funding secured and regulatory approval in place, Pragmatech’s immediate focus is on commercial deployment of iAST® across Spanish and European hospitals.
The company is also expected to continue investing in product development, clinical validation, and partnerships within the healthcare ecosystem.
As pressure grows on healthcare systems to improve antibiotic stewardship, AI-driven decision-support tools like iAST® are likely to play an increasingly central role in clinical practice.
Also Read: Alvotech secures €100 million term loan to support R&D and global growth